ADVERTISEMENT
Durvalumab Plus Chemotherapy Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
Findings from a recent study revealed durvalumab plus chemotherapy isnot be a cost-effective first-line treatment option for patients with extensive-stage small cell lung cancer (SCLC; J Natl Compr Canc Netw. 2021; jnccn20454. doi:10.6004/jnccn.2020.7796).
The CASPIAN trial demonstrated positive results in overall survival for patients with extensive-stage small cell lung cancer who were treated with durvalumab plus chemotherapy, however, cost-effectiveness was not observed.
Dong Ding, MM, Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, and colleagues constructed a comprehensive Markov model in order to compare the cost and effectiveness of durvalumab plus chemotherapy vs platinum/etoposide alone in the first-line therapy of extensive-stage SCLC from the US healthcare system perspective.
The Markov model used data from the CASPIAN trial. Total costs, life years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were examined.
The model revealed an additional 0.27 life years and 0.20 QALYs associated with durvalumab plus chemotherapy over the chemotherapy treatment. Durvalumab + chemotherapy therapy resulted in an ICER of $464,711.90 per QALY.
“Durvalumab in combination with platinum/etoposide is not a cost-effective option in the first-line treatment of patients with extensive-stage SCLC,” Mr Ding and colleagues concluded.—Marta Rybczynski
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement